XENOTHERA

Description

XENOTHERA is a clinical stage biotech company developing First-In-Class drugs mainly in oncology and haematology. Our disruptive immunotherapy, based on a patented platform of Glyco-Humanized Polyclonal Antibodies (GH-pAb), addresses major unmet medical needs, especially in solid and liquid tumours. XENOTHERA develops two main assets: LIS1, in Peripheral T-cell lymphoma (FPI summer 2024) and in Solid Organ Transplantation (confirmatory pivotal trial in preparation) and XON7, a pan-cancer GH-pAb targeting solid tumors, in clinic with Clinical trials that started in Novembre 2023.

Company members

Philippe Rousseau, CEO

HealthTech Innovation Days - 6th edition is an event organized by HealthTech For Care.

HealthTech For Care is an endowment fund (non-for profit organization) whose primary mission is to advocate for universal access to healthcare for all European patients, with a specific focus on advanced medical technologies and innovative drugs. The fund's initiatives and events with a European dimension gather all stakeholders involved in the health innovation value chain, fostering better coordination within the European health ecosystem. HealthTech For Care is administered by a board of European experts.

For any request: contact@htfc-eu.com
Where to find us? Healthtech For Care, 10 Place de Catalogne, 75014 Paris

XENOTHERA

Description

Company members

© HealthTech For Care 2022-2024 - All rights reserved

Cookies Policy

Legal notice

Privacy Policy